A new era in the treatment of urothelial carcinoma
1Department of Hematology and Oncology, Weill Cornell Medicine, New York, NY; Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, NY.
Abstract:
The advances in targeted therapies, immunotherapy, and the recent emergence of antibody-drug conjugates (ADCs) herald a potential paradigm shift in treating patients with metastatic urothelial cancer. Yet, there are inherent challenges in utilizing these therapies, including the management of treatment-related toxicities. In this special Urologic Oncology: Seminars and Original Investigations issue, we review the latest developments and discuss insights into future research needs.
Related Concept Videos
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi III: Medical Management
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Infection IV: Nursing Management


